Acute Pancreatitis Associated With the Use of Peginterferon

Özdoğan, Osman; Tahan, Veysel; Cincin, Altug; İmeryüz, Neşe; Tözün, Nurdan

doi:10.1097/mpa.0b013e3180333afb

Cited by 16 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, such patients developed acute pancreatitis within hours of being rechallenged with IFN a-2b. Acute pancreatitis has been reported in 3 cases of HCV-infected patients treated with PEG-IFN plus RBV therapy [2,3,4]; however, its pathogenesis has not been described.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load

Ando

Kim

Imoto

et al. 2009

Case Rep Gastroenterol

View full text Add to dashboard Cite

Acute pancreatitis, an uncommon side effect of pegylated interferon α (PEG-IFN α) and ribavirin (RBV) combination therapy, has rarely been reported in the English language literature. Here, acute pancreatitis associated with PEG-IFN plus RBV treatment is described in three patients with chronic hepatitis C, genotype 1b with high serum hepatitis C virus RNA levels. The patients had been started on weekly subcutaneous injections of PEG-IFN α (60, 80, and 90 μg) plus a daily oral dose of RBV (600 mg). The therapy was discontinued, however, because of the onset of acute pancreatitis (after 15 weeks, 48 weeks, and 3 weeks respectively). The drug-induced pancreatitis was diagnosed on the basis of elevated levels of amylase and lipase and the absence of other identifiable causes. High tumor necrosis factor-α was found in one patient and high interleukin-6 in the other two. The immune system stimulated by PEG-IFN and RBV combination therapy might have caused the acute pancreatitis. Further study is needed to clarify the mechanism of the onset of drug-induced pancreatitis by PEG-IFN and RBV combination therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has been described in three cases of hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN) plus RBV [2,3,4]. The pathogenesis of acute pancreatitis related to a stimulated immune system, however, has not been described.…”

Section: Introductionmentioning

confidence: 99%

Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load

Ando

Kim

Imoto

et al. 2009

Case Rep Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The search showed 4 articles where there were a total of 13 report cases demonstrating acute pancreatitis developed during treatment for CHC3 – 6 Acute pancreatitis developed within 5 months (1–21 weeks) after the initiation of the treatment. All of them (except one that used IFN isolated) reported IFN and RBV combination treatment as the potential cause of drug-induced pancreatitis in these patients.…”

Section: Discussionmentioning

confidence: 99%

Acute pancreatitis during interferon-alpha and ribavirin treatment for hepatitis C

Silva

Giroldi²,

Basso³

et al. 2009

Case Reports

View full text Add to dashboard Cite

A patient treated with interferon-alpha and ribavirin for hepatitis C, who developed acute pancreatitis, is presented here along with a literature review. A 45-year-old Caucasian man was admitted to the intensive care unit because of an acute pancreatitis. According to the adverse drug reaction probability scale, it is probable that pancreatitis was induced by treatment (interferon and ribavirin) for chronic hepatitis C (CHC) commenced 2 months ago. We performed a literature search of all available English-language articles published on MEDLINE between January 1966 and July 2008 using the key terms "acute pancreatitis", "interferon" and "ribavirin"; only four papers were found with a total of 13 reported cases demonstrating acute pancreatitis developed during treatment for CHC. Looking out for the minimal clinical signs and symptoms of acute pancreatitis in patients with CHC using interferon and ribavirin can help to detect this relevant and rare adverse drug reaction early.

show abstract

“…The reported cases in the literature are acute pancreatitis cases developed in patients using IFN alpha or peg-IFN alpha-2b for CHC (1,3,4,5,6,7,10,11,12). On the other hand, one case of acute pancreatitis induced by peg-IFN in CHB has also been reported (8).…”

Section: Discussionmentioning

confidence: 99%

“…Development of acute pancreatitis is a very rare complication seen during IFN (pegylated or standard) treatment of chronic viral hepatitis (1,2). In the literature, when concurrent cases with HIV infection are excluded, development of acute pancreatitis is reported in 49 cases due to standard IFN alpha and 5 cases due to peg-IFN alpha-2b plus ribavirin treatment in CHC patients (3,4,5,6,7). On the other hand, there is only one reported case of acute pancreatitis occurring during IFN treatment of CHB (8).…”

Section: Introductionmentioning

confidence: 99%

Development of Acute Pancreatitis Due to Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis B: A Case Report

Köse¹,

Türken²,

Tanrısev³

et al. 2015

vhd

View full text Add to dashboard Cite

Acute Pancreatitis Associated With the Use of Peginterferon

Cited by 16 publications

References 8 publications

Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load

Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load

Acute pancreatitis during interferon-alpha and ribavirin treatment for hepatitis C

Development of Acute Pancreatitis Due to Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis B: A Case Report

Contact Info

Product

Resources

About